Controversy ⚖️
Pre-symptomatic #MultipleSclerosis or radiologically isolated syndrome #RIS should be actively monitored and treated.
🧵1/4
Link to commentary ▶️ https://t.co/1jwvc6HoQS
Not all MS drugs are created equal! In MS Center ErasMS gebruiken we daarom vanaf nu de Nederlandse versie van de #clinicspeak medicatie keuzetool. Vrij beschikbaar voor alle MS centra en pmMS. DM voor een visitekaartje! https://t.co/3o32TDKFP8
Very 🔥 debate with @XtineLebrunF and @drBWillekens on a late breaking topic: should we start treating radiologically isolated syndrome? A struggle between biology and disease, that needs to be addressed by new RIS criteria. @ECTRIMS
In simulated MS cohorts, lesion detection algorithms argue to be disease-modifying by detection more lesions, triggering early treatment switches and preventing disability. Nice feature or necessary add-on intervention?
https://t.co/bALFi2FIXr
Rituximab (anti-CD20) is a more potent MS drug than dimethyl fumarate. The bigger question: is it better than the more costly ocrelizumab? Three possible answers: an official, a real and a right one. Which one do you prefer?@the_MSBlog https://t.co/juIWL45eWi
@MichaelRobersMD @ErasMS_Rdam Agree, it probably won’t be different for B cell tx, but my hope is we could evolve towards ‘focused retreatment’ with anti-CD20 based on a biomarker such as NfL
There’s no exit strategy for pwMS on anti-CD20 atm. Some argue there’s no need to exit, some argue to extend intervals and we argue to stop anti-CD20 after 4 infusion cycli. Do you agree? https://t.co/Jk4WLLv3sI @ErasMS_Rdam
The position of aHSCT in the MS treatment landscape is a source of debate, and for many pwMS it’s unclear who can benefit. In early aggressive MS it’s clear, but for progressive MS the risk/benefit profile of aHSCT shifts. @the_MSBlog https://t.co/i2No9H6KuK
During clincics, we are often too much focused on drugs, and forget to mention the second most-effective MS treatment: exercise. To compensate, I discuss my insights together with @themsguide in this podcast. #brainhealth
https://t.co/axuomUiIvl
Many pwMS need to gain a new expertise: overcoming administrative hurdles to gain access to crucial healthcare services such as rehab. In the UK this is the red tape, in the Netherlands a purple crocodile. Do you have any in your pool? https://t.co/HN6MmCYxC8 @ErasMS_Rdam
This is a superb post. I also struggle to understand why someone would fail to take the neurologist's advice. I guess @SmetsIde has put her finger on it when she suggests it may be a form of denial (my words).
MS is constantly vandalising our brains.
https://t.co/qG9uLU9wXn
Many pwMS struggle with DMT decisions when they have new lesions on brain MRI without new symptoms. Two attempts to better explain this clinical-MRI paradox: the topographical model of MS and road traffic. Do you stop for groceries at night? @the_MSBlog https://t.co/kg8kdMRdyb
A huge thanks to all the people with MS who helped us to design this leaflet for people with MS considering pregnancy https://t.co/QMrfQXUrvK. You had told us you wanted a reliable leaflet to be able to look at outside of clinic appointments that you could read in your own time.